BioMarin Pharmaceutical Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 BioMarin Pharmaceutical Inc 公司

BioMarin Pharmaceutical Inc. (BioMarin) 是一家生物技術公司，致力於開發和商業化解決遺傳病根源的療法。BioMarin 的商業產品包括 Vimizim (elosulfase alpha)、Naglazyme (galsulfase)、Palynziq (pegvaliase-pqpz)、Brineura (cerliponase alfa)、Aldurazyme (laronidase)、Roctavian (valoctocogene roxaparvovec)、Kuvan (sapropterin dihydrochloride) 和 Voxzogo (vosoritide)。Vimizim 是一種酶替代療法，用於治療溶酶體貯積症 MPS IVA。Roctavian 是一種腺相關病毒 (AAV5) 載體基因療法，旨在恢復重度血友病 A 患者的血漿因子 VIII 濃度。Voxzogo 是一種每日一次注射的 C 型利鈉肽 (CNP) 類似物，用於治療軟骨發育不全。 Brineura 是一種重組人三肽基肽酶 1 (TPP1)，用於治療患有 CLN2（一種巴頓病）的患者。

BioMarin Pharmaceutical Inc簡介



公司代碼BMRN

公司名稱BioMarin Pharmaceutical Inc

上市日期Jul 23, 1999

CEOMr. Alexander Hardy

員工數量3040

證券類型Ordinary Share

年結日Jul 23

公司地址770 Lindaro Street

城市SAN RAFAEL

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編94901

電話14155066700

網址https://www.biomarin.com/

公司代碼BMRN

上市日期Jul 23, 1999

CEOMr. Alexander Hardy

BioMarin Pharmaceutical Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

62.99K

-53.04%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-7.06%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

Dr. Athena M. Countouriotis, M.D.

Independent Director

8.83K

+305.05%

Ms. Barbara W. Bodem

Independent Director

8.83K

+305.05%

Ms. Elizabeth Mckey Anderson

Independent Director

--

Mr. Timothy Walbert

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

62.99K

-53.04%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-7.06%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Voxzogo

221.39M

27.23%

Vimizim

215.42M

26.50%

Naglazyme

128.87M

15.85%

Palynziq

105.94M

13.03%

Aldurazyme

56.44M

6.94%

其他

84.92M

10.45%

地區USD

名稱

營收

佔比

United States

272.55M

33.53%

Europe

243.14M

29.91%

Rest of the world

142.74M

17.56%

Latin America

98.12M

12.07%

ALDURAZYME net product revenues marked by Sanofi

56.44M

6.94%

業務

地區

業務USD

名稱

營收

佔比

Voxzogo

221.39M

27.23%

Vimizim

215.42M

26.50%

Naglazyme

128.87M

15.85%

Palynziq

105.94M

13.03%

Aldurazyme

56.44M

6.94%

其他

84.92M

10.45%

股東統計

更新時間: 8月16日週六

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

9.84%

BlackRock Institutional Trust Company, N.A.

9.39%

PRIMECAP Management Company

8.21%

Dodge & Cox

7.86%

Viking Global Investors LP

6.40%

其他

58.30%

持股股東

佔比

The Vanguard Group, Inc.

9.84%

BlackRock Institutional Trust Company, N.A.

9.39%

PRIMECAP Management Company

8.21%

Dodge & Cox

7.86%

Viking Global Investors LP

6.40%

其他

58.30%

股東類型

持股股東

佔比

Investment Advisor

43.91%

Investment Advisor/Hedge Fund

40.30%

Hedge Fund

7.65%

Pension Fund

3.13%

Research Firm

1.58%

Sovereign Wealth Fund

1.23%

Bank and Trust

1.14%

Individual Investor

0.75%

Venture Capital

0.34%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

1304

191.42M

99.64%

-19.19M

2025Q2

1333

195.10M

101.61%

-16.01M

2025Q1

1355

191.53M

99.87%

-20.72M

2024Q4

1336

190.53M

99.88%

-17.50M

2024Q3

1308

188.26M

98.81%

-22.17M

2024Q2

1293

192.58M

101.18%

-14.21M

2024Q1

1278

194.24M

102.38%

-11.23M

2023Q4

1294

193.16M

102.42%

-3.22M

2023Q3

1275

188.66M

100.18%

-4.68M

2023Q2

1283

185.80M

98.76%

-8.08M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

18.91M

9.85%

-8.07K

-0.04%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

18.04M

9.39%

-79.52K

-0.44%

Jun 30, 2025

PRIMECAP Management Company

15.77M

8.21%

-2.00M

-11.26%

Jun 30, 2025

Dodge & Cox

15.11M

7.87%

+153.07K

+1.02%

Jun 30, 2025

Viking Global Investors LP

12.29M

6.4%

+1.49M

+13.78%

Jun 30, 2025

State Street Investment Management (US)

8.85M

4.61%

+384.66K

+4.55%

Jun 30, 2025

AQR Capital Management, LLC

5.58M

2.91%

+2.65M

+90.74%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.47M

1.81%

+43.19K

+1.26%

Jun 30, 2025

Millennium Management LLC

2.83M

1.48%

+2.16M

+319.74%

Jun 30, 2025

Rothschild & Co Asset Management Europe SCS

1.97M

1.03%

-20.00

-0.00%

Aug 31, 2025

持股ETF



更新時間: 10月6日週一

機構名稱

佔比

Invesco Biotechnology & Genome ETF

4.74%

Global X Genomics & Biotechnology ETF

3.43%

First Trust NYSE Arca Biotechnology Index Fund

3.25%

Goldman Sachs Future Health Care Equity ETF

2.85%

SPDR S&P Biotech ETF

2.37%

WealthTrust DBS Long Term Growth ETF

2.11%

Alger Russell Innovation ETF

1.9%

First Trust Health Care Alphadex Fund

1.82%

Pacer Lunt MidCap Multi-Factor Alternator ETF

1.71%

Virtus LifeSci Biotech Products ETF

1.69%

Invesco Biotechnology & Genome ETF

佔比4.74%

Global X Genomics & Biotechnology ETF

佔比3.43%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.25%

Goldman Sachs Future Health Care Equity ETF

佔比2.85%

SPDR S&P Biotech ETF

佔比2.37%

WealthTrust DBS Long Term Growth ETF

佔比2.11%

Alger Russell Innovation ETF

佔比1.9%

First Trust Health Care Alphadex Fund

佔比1.82%

Pacer Lunt MidCap Multi-Factor Alternator ETF

佔比1.71%

Virtus LifeSci Biotech Products ETF

佔比1.69%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據